Clinical development of VAC2 is being conducted through a partnership with Cancer Research UK (CRUK), who is responsible for costs and to conduct manufacturing and the clinical trial. Currently, enrollment is ongoing in a Phase 1 study of VAC2 in advanced and resected non-small cell lung cancer (NSCLS). The primary endpoint of this study is safety and tolerability of 6 intradermal injections. In May 2020, Lineage announced the early exercise of its option with Cancer Research UK for this immune-oncology cell therapy program as well as a platform expansion to include coronavirus vaccine development.
In October 2020, Lineage announced encouraging preliminary results from the ongoing Phase 1 clinical study of VAC2 in NSCLC. VAC2 demonstrated remarkably potent induction of immune responses in all patients dosed to date, with high levels of peripheral antigen-specific immunogenicity observed at multiple time points and confirmed by multimer staining. VAC2 also appears to be well tolerated with no unexpected adverse events reported. On the basis of these findings, and following completion of the ongoing VAC2 clinical study in NSCLC, the Company will seek to evaluate VAC2 in combination with therapies considered biologically complementary to VAC2, such as chemotherapy and the immune cell protectant properties offered by anti-PD1 immunotherapy.
In April 2021, Lineage announced a worldwide license and development collaboration agreement with Immunomic Therapeutics, Inc. to generate a novel product candidate derived from Lineage’s VAC allogeneic cancer immunotherapy platform and targeting a proprietary Tumor Associated Antigen (TAA) construct provided by Immunomic for the treatment of glioblastoma multiforme (GBM).